Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.
Invest Ophthalmol Vis Sci. 2011 May 9;52(6):3046-50. doi: 10.1167/iovs.10-5842.
To investigate whether intravitreal ranibizumab (0.05 mL) treatment affects retinal vessel diameters and retrobulbar blood velocities in patients with acute branch retinal vein occlusion (BRVO).
Thirty patients with clinically significant macular edema secondary to BRVO were included. The duration of the study was three months. Patients were studied before and one week, one month, two months, and three months after the first ranibizumab injection. Depending on the clinical requirements, up to three ranibizumab injections were administered. Retinal vessel diameters were measured using a retinal vessel analyzer. Flow velocities in the retrobulbar central retinal artery were measured using color doppler imaging. Best-corrected visual acuity was assessed using ETDRS charts. Measurements were done in the affected as well as in the contralateral eye.
Three patients were lost for follow up. In the remaining 27 patients, significant vasoconstriction was observed in retinal veins (P < 0.001 versus baseline) and in retinal arteries (P = 0.001 versus baseline) of the affected eyes. In addition, a significant reduction in flow velocities was observed in the BRVO eyes over time (peak systolic velocity: P = 0.003, end diastolic velocity: P = 0.003). The reduction in retinal vessel diameters and flow velocities did not correlate with changes in visual acuity or number of re-treatments. In the contralateral eyes no change in retinal blood flow parameters was seen.
BRVO is an ischemic retinal disease. Given that ranibizumab treatment reduces retinal perfusion in these eyes the potential long-term effects of this vasoconstriction need to be considered.
研究玻璃体内雷珠单抗（0.05ml）治疗是否会影响急性视网膜分支静脉阻塞（BRVO）患者的视网膜血管直径和球后血流速度。
纳入 30 例因 BRVO 引起的临床显著黄斑水肿患者。研究持续时间为 3 个月。患者在首次雷珠单抗注射前和注射后 1 周、1 个月、2 个月和 3 个月进行检查。根据临床需要，最多可给予 3 次雷珠单抗注射。使用视网膜血管分析仪测量视网膜血管直径。使用彩色多普勒成像测量球后中央视网膜动脉的血流速度。使用 ETDRS 图表评估最佳矫正视力。对患眼和对侧眼进行测量。
3 例患者失访。在其余 27 例患者中，患眼的视网膜静脉（P<0.001 与基线相比）和视网膜动脉（P=0.001 与基线相比）明显收缩。此外，随着时间的推移，BRVO 眼中的血流速度显著降低（收缩期峰值速度：P=0.003，舒张末期速度：P=0.003）。视网膜血管直径和血流速度的降低与视力变化或再治疗次数无关。对侧眼的视网膜血流参数无变化。
BRVO 是一种缺血性视网膜疾病。鉴于雷珠单抗治疗降低了这些眼中的视网膜灌注，需要考虑这种血管收缩的潜在长期影响。
